Clinical trial NCT03162094: Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
Official title: A Phase I/II, Double-blind, Placebo-controlled Study Assessing the Safety and Efficacy of AVX-012 Ophthalmic Solution in Subjects With Mild-to-moderate Dry Eye Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Dry Eye Syndrome
Lead sponsor: Avizorex Pharma, S.L.
Sponsor class: INDUSTRY
First posted: 2017-05-22
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase I: patient will be included on 3 arms of treatment ( Placebo, Low dose or High dose AVX-012) TID

Phase II: Patient will be included on 4 arms of treatment (Placebo/Dose) BID/TID
Primary purpose: TREATMENT

Brief summary: This is a first-in-human phase I/II randomized, double-blind, placebo (vehicle)-controlled, multicenter study to assess the Safety and Efficacy of AVX-012 Ophthalmic Solution in subjects with Mild-to-Moderate Dry Eye Syndrome.

The study consists of two parts (part A and part B):

Detailed description: The study part A will be an early safety assessment of AVX-012 ophthalmic solution (Low dose and High dose AVX-012) administered three times per day (TID) when compared with the vehicle (placebo). Approximately 24 patients will be randomized 1:1:1 to study groups (Low dose AVX-012, High dose AVX-012, or placebo \[vehicle\]).

An independent safety committee will be in charge of assessing the safety of study treatments to proceed to part B.

The study part B will be an efficacy and safety assessment of the dose of AVX-012 ophthalmic solution selected in the study part A (Low dose or High dose AVX-012) administered three times a day (TID) and twice a day (BID) when compared with the vehicle (placebo). Approximately 148 patients will be randomized 1:1:1:1 to study groups (Low dose or High dose AVX-012 and placebo \[vehicle\], TID and BID).

Eligibility criteria: Inclusion Criteria:

* Male or female subjects of at least 18 years of age.
* Diagnosis of dry eye (by a health care professional) for at least 3 months prior to screening visit.
* Normal lid anatomy.
* Intraocular pressure less than 22 mmHg (inclusive) in each eye.
* Best-corrected visual acuity measured by ETDRS in each eye of 20/200 (logMAR 1.0) or better.
* Schirmer I test score of ≥ 3 mm to ≤ 9 mm/ 5 min (with anesthesia).
* SANDE symptom score of 50 or more.
* Total ocular staining of minimum 1 in Oxford scale with fluorescein and/or green lissamine.
* Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements.

Exclusion Criteria:

* History of other than dry eye, ocular surface of moderate to severe Meibomian gland disease (grades +++ to ++++ \[moderately to severely altered expressibility and secretion quality\]: moderate symptoms with mild to moderate corneal staining, mainly peripheral; or marked symptoms with marked corneal staining, central in addition), chronic, or acute ophthalmic disease in either eye, including glaucoma, macular degeneration, clinically significant cataract (primary or secondary).
* Best-corrected visual acuity score of 55 letters read or lower in each eye as measured by ETDRS (letters read method).
* Previous history of drug or any ingredient hypersensitivity.
* Intraocular or strabismus surgery or glaucoma laser surgery within the previous 6 months.
* History of refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, etc.).
* Ocular trauma within the past 6 months.
* Relevant ocular pathology judged by the investigator such as; eyelid anomalies, corneal disorders, metaplasia of the ocular surface, current filamentous keratitis, or corneal neovascularization.
* Any history of herpes simplex or herpes zoster keratitis.
* Ocular infection (bacterial, viral, or fungal)
* Ocular medication of any kind, with the exception of artificial tears/gels/lubricants within the past 2 weeks of screening.
* Cyclosporine treatment during the 6 months prior to enrolment.
* Use of systemic medication that might cause dryness in the eye as a secondary effect (such as antihistaminics, hormone replacing therapies, etc.).
* Use of contact lens
* Use of additional artificial tears (other than study treatments) throughout the study, starting at screening visit.
* Participation in an investigational drug or device trial within the 30 days previous to screening visit.
* Any abnormality preventing reliable applanation tonometry of either eye.
* Central corneal thickness greater than 600 μm by conventional pachymetry.
* Signs of severe ocular surface diseases including corneal or conjunctival staining judged as severe by the investigator.
* Clinically significant systemic disease including uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular, endocrine disorders, previous cerebrovascular accident with a significant residual motor or sensory defect, progressive neurologic disorders (Parkinsonism, dementias, multiple sclerosis, unstable acquired seizure disorders) which might interfere with the study as judged by the investigator.
* Any systemic disease or medication that might course with known dryness in the eye.
* Changes of systemic medication that could have a substantial effect on intraocular pressure within 30 days prior to screening or anticipated during the study.
* Any medical condition (systemic or ophthalmic) that may, in the opinion of the investigator, preclude the safe administration of the investigational product or safe participation in this study.
* Pregnant or breastfeeding females or those with a positive pregnancy test.
* All females of childbearing potential must have a negative urine pregnancy test result at screening, and also agree to abstain from sexual intercourse with a male partner or agree to use a medically acceptable method of birth control (such as condom, diaphragm or cervical/vault cap with spermicide) until 28 days post-treatment. Males should also agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide until 28 days post-treatment.

Primary outcomes:
measure: The objective of part A is to evaluate the safety of AVX-012 ophthalmic solution in subjects with dry eye syndrome.
timeFrame: 7 days (+1 day)
measure: The objective of part B is to evaluate the efficacy of AVX-012 ophthalmic solution in treating symptoms of dry eye.
timeFrame: 28 days (+7 days)
Secondary outcomes:
measure: Confirm the safety of AVX-012 ophthalmic solution in subjects with dry eye syndrome.
timeFrame: 28 days (+7 days)
measure: Change from baseline in corneal staining score
timeFrame: 28 days (+7 days)
measure: Change from baseline in Schirmer I test score
timeFrame: 28 days (+7 days)
measure: Change from baseline in tear film break up time score
timeFrame: 28 days (+7 days)
measure: Change from baseline in conjunctival staining score
timeFrame: 28 days (+7 days)
Other outcomes:
Locations:
city: Jerez De La Frontera
country: Spain
facility: Clinica Oftalvist Jerez
state: Cadiz
city: Pamplona
country: Spain
facility: Clínica Universitaria de Navarra
state: Navarra
city: Alicante
country: Spain
facility: Clínica Oftalvist Vistahermosa
city: Barcelona
country: Spain
facility: Innova Ocular ICO Barcelona
city: Barcelona
country: Spain
facility: Centro de Oftalmologia Barraquer
city: Barcelona
country: Spain
facility: H Vall de Hebron
city: Barcelona
country: Spain
facility: H Clinic
city: Barcelona
country: Spain
facility: H General de Cataluña
city: Barcelona
country: Spain
facility: H Germas Trias Pujol
city: Granada
country: Spain
facility: clínica Oftalvist Granada
city: Madrid
country: Spain
facility: Clínica Universitaria de Navarra_ Madrid
city: Madrid
country: Spain
facility: Clínica Oftalvist Moncloa
city: Madrid
country: Spain
facility: H Universitario Ramón y Cajal
city: Madrid
country: Spain
facility: H Clínico San Carlos
city: Murcia
country: Spain
facility: Hospital General Universitario Reina Sofía
city: Oviedo
country: Spain
facility: Instituto Oftalmológico Fernández Vega
city: Valencia
country: Spain
facility: clinica Oftalvist Valencia
city: Valencia
country: Spain
facility: Hospital Universitario La Fé
city: Valladolid
country: Spain
facility: Instituto Universitario de Oftalmobiología Aplicada (IOBA)
city: Zaragoza
country: Spain
facility: H Miguel Servet
city: Zaragoza
country: Spain
facility: H Universitario Lozano Blesa
Study officials:
affiliation: Avizorex Pharma, S.L.
name: Patrick Tresserras
role: STUDY_DIRECTOR
References: